Peptide Therapeutics Market (2026-2036)

The growth of this market is mainly driven by the rapid expansion of GLP-1 and incretin peptides for diabetes and obesity, the rising global burden of metabolic and chronic diseases, the growing success of peptides in rare and endocrine diseases, and advances in peptide engineering that extend half-life and enable new routes of administration. However, the injection burden and poor oral bioavailability of most peptides, the complexity and cost of peptide manufacturing, pricing pressure and generic erosion, and competition from compounded and unapproved peptide products restrain the growth of this market.

Furthermore, oral and macrocyclic peptides, peptide conjugates and radioligand therapies, and the generic peptide and outsourced manufacturing opportunity created by patent expiries are expected to offer growth opportunities for the stakeholders in this market. However, the environmental footprint of peptide synthesis, impurity and immunogenicity control for complex generics, short half-lives and delivery limitations, and competition from small molecules and other modalities remain major challenges impacting the growth of this market. Additionally, the rise of multi-agonist incretin peptides, the shift toward oral and macrocyclic peptides, the global race for peptide manufacturing capacity, and the adoption of greener and hybrid manufacturing technologies are prominent trends in this market.

The Peptide Therapeutics Market comprises approved medicines whose active ingredient is a peptide, typically a chain of about 2 to 50 amino acids, including linear, cyclic, lipidated, and conjugated peptides, produced by chemical synthesis or recombinant technology. The market covers GLP-1 and incretin peptides such as semaglutide, tirzepatide, liraglutide, and dulaglutide; hormone analogs, including GnRH analogs such as leuprolide and goserelin, somatostatin analogs such as octreotide and lanreotide, parathyroid hormone analogs such as teriparatide, abaloparatide, and palopegteriparatide, calcitonin, vasopressin and oxytocin analogs, and the C-type natriuretic peptide analog vosoritide; oncology peptides, including the proteasome inhibitor carfilzomib and peptide receptor radionuclide therapies; immunomodulatory and complement peptides such as glatiramer acetate, pegcetacoplan, and zilucoplan; gastrointestinal peptides such as linaclotide, plecanatide, and teduglutide; and anti-infective peptides. Insulins and larger proteins, small-molecule drugs that act on peptide receptors, such as oral small-molecule GLP-1 agonists, and peptide vaccines are excluded. The ecosystem spans innovator pharmaceutical companies, generic manufacturers, peptide API producers and contract development and manufacturing organizations, amino acid and reagent suppliers, device makers, pharmacies, and regulators.

GLP-1 and incretin peptides dominate the market. Eli Lilly's tirzepatide franchises generated USD 22.97 billion for Mounjaro and USD 13.54 billion for Zepbound in 2025, growing 99% and 175% respectively and together representing about 56% of Lilly's total revenue of USD 65.2 billion, while Novo Nordisk's semaglutide franchises, Ozempic, Wegovy, and Rybelsus, remain among the world's best-selling medicines. GLP-1 and incretin peptides accounted for about three-quarters of peptide therapeutics sales in 2025. At the same time, pricing pressure is rising, with Lilly reporting that lower realized prices reduced its U.S. diabetes and obesity revenue by about 5% in the fourth quarter of 2025, and semaglutide patents expiring in 2026 in markets including China, India, Canada, and Brazil, opening the door to generic versions.

Beyond incretins, peptides are established in oncology, endocrinology, rare diseases, gastroenterology, and immunology. BioMarin's Voxzogo, a C-type natriuretic peptide analog that became the first approved therapy to increase growth in children with achondroplasia, grew 26% in 2025 across 55 markets, and Amgen's proteasome inhibitor Kyprolis generated USD 378 million in the second quarter of 2025. Long-standing peptide drugs such as leuprolide, octreotide, lanreotide, teriparatide, glatiramer acetate, and linaclotide remain important, many facing generic competition, and newer peptides for rare endocrine and complement-mediated diseases, such as palopegteriparatide for hypoparathyroidism and pegcetacoplan for geographic atrophy and paroxysmal nocturnal hemoglobinuria, are expanding the market.

Technology and manufacturing are reshaping the industry. Oral peptides have reached the market with oral semaglutide, including the oral Wegovy tablet approved in December 2025, and macrocyclic oral peptides targeting PCSK9 and the IL-23 receptor have delivered positive Phase 3 results. Demand for GLP-1 peptides has triggered a global race for manufacturing capacity, including Novo Holdings' USD 16.5 billion acquisition of Catalent in 2024 and Lilly's multibillion-dollar investments in new plants, while contract manufacturers such as Bachem, PolyPeptide, CordenPharma, and WuXi TIDES are expanding solid-phase and liquid-phase peptide synthesis capacity. With the International Diabetes Federation estimating about 589 million adults with diabetes worldwide in 2024 and the World Health Organization estimating that more than 1 billion people live with obesity, the long-term demand outlook for peptide therapeutics remains strong.